Earnings Ahead

PTGX - Protagonist Therapeutics, Inc.

28.08 -0.67 -2.33

  1. Home
  2. Healthcare
  3. PTGX
Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

About

Profile

Headquarters

Newark, California, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

PTGX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Protagonist GAAP EPS of -$0.68 misses by $0.03
  • Johnson & Johnson psoriasis pill disappoints in phase 2 trial
  • Protagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseases
  • Protagonist GAAP EPS of -$0.67 in-line
  • Protagonist Therapeutics prices $100M offering
  • Protagonist falls on $100M public offering
  • Protagonist GAAP EPS of -$0.69 misses by $0.10
  • Sangamo, Protagonist, and Eiger among biotechs with exposure to Silicon Valley Bank
  • Johnson & Johnson, Protagonist succeed in mid-stage trial for psoriasis candidate
  • CDTX, PTGX and TAST among premarket gainers
  • Protagonist GAAP EPS of -$0.64 beats by $0.23
  • Protagonist GAAP EPS of -$0.84 beats by $0.10
  • Protagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65M
  • Protagonist hits 52-week low as Street reacts to data for ulcerative colitis candidate
  • Protagonist falls on data from phase 2 study of PN-943 to treat ulcerative colitis
  • Protagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertide
  • Asif Ali is the new finance chief at Protagonist Therapeutics
  • Protagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62M
  • Protagonist chooses candidate to advance into phase 2 in collaboration with Janssen
  • Phase 2a data supports Protagonist genetic liver disease drug rusfertide
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
November 3, 2021 -0.7 / -0.67 10.29M / 1.74M Beat!
August 4, 2021 -0.69 / -0.5455 2.27M / 5.17M
May 4, 2021 -0.54 / -0.568 6.19M / 1.5M Beat!
March 10, 2021 -0.48 / -0.478 5.65M / 2.7M Beat!
November 4, 2020 -0.21 / -0.6125 13.11M / 2.87M Beat!
August 6, 2020 -0.59 / -0.57 6.22M / 2.95M Beat!
May 7, 2020 -0.72 / -0.69 3.65M / 1.48M Beat!
March 10, 2020 -0.63 / -0.65 2.72M / 4.23M
Date Price Open High Low Vol Change ER
Mar 8 24.01 23.99
24.32
22.93
988.03K 0.67%
Mar 7 23.85 24.70
24.98
23.19
590.45K -1.89%
Mar 4 24.31 25.68
26.43
24.20
396.11K -7.39%
Mar 3 26.25 26.66
27.15
25.87
922.78K -1.24%
Mar 2 26.58 25.95
27.52
25.02
755.78K 1.26%
 
Mar 1 26.25 24.29
27.97
24.29
829.36K 8.11%
Feb 28 24.28 24.12
25.28
23.93
362.24K -0.86%
Feb 25 24.49 24.34
25.08
23.91
539.48K 0.99%
Feb 24 24.25 22.77
24.33
22.56
2.11M 3.90%
Feb 23 23.34 24.40
24.56
23.21
575.58K -4.34%
Feb 22 24.40 24.33
25.27
24.33
662.73K -1.81%
Feb 18 24.85 25.50
26.04
24.57
468.27K -2.43%
Feb 17 25.47 26.35
27.37
25.15
670.36K -4.61%
Feb 16 26.70 28.49
28.92
26.56
499.96K -7.07%
Feb 15 28.73 28.36
28.88
26.97
2.84M 5.01%
Feb 14 27.36 27.28
28.58
27.16
1.35M -1.76%
Feb 11 27.85 28.00
29.13
27.78
597.83K 1.46%
Feb 10 27.45 28.16
28.52
26.91
841.39K -3.38%
Feb 9 28.41 28.26
29.25
27.87
695.75K 1.76%